Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Comparative Efficacy and Safety of Fenoverine (FEN-401)

This study has been completed.
Information provided by (Responsible Party):
Bukwang Pharmaceutical Identifier:
First received: January 5, 2012
Last updated: December 17, 2014
Last verified: December 2014

It is a randomized double-blind parallel phase IV study to compare Fenoverine and Trimebutine maleate in the efficacy and safety.

Study Hypothesis: Fenoverine is non-inferior to Trimebutine maleate in its efficacy and safety.

Condition Intervention Phase
Irritable Bowel Syndrome
Drug: Fenoverine
Drug: Timebutine
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Comparative Efficacy and Safety of Fenoverine and Trimebutine Maleate in Irritable Bowel Syndrome; A Randomized Double-blind Parallel Multi-center Phase IV Trial

Further study details as provided by Bukwang Pharmaceutical:

Primary Outcome Measures:
  • the proportion of subjects with improvement in abdominal pain or discomfort [ Time Frame: week 8 ]
    the proportion of subjects who experienced more than 30% improvement in abdominal pain or discomfort score with visual analog scale at week 8 compared to baseline

Secondary Outcome Measures:
  • BSS scores (each and total) [ Time Frame: week 4, 8 ]
    BSS score will be checked for four IBS symptoms; abdominal pain or discomfort, bloating, constipation, diarrhea. The scores will be compared for its chronological changes between trial groups. Total BSS score will be the sum of the scores of four symptoms measured.

  • overall BSS score [ Time Frame: Week 4, 8 ]
    IBS symptom will be assessed overally by subjects at day 1, week 4, and week 8. The scores will be compared chronologically between groups.

  • subject's satisfaction with treatment [ Time Frame: week 4, 8 ]
    Subject's satisfaction with the treatment is measured using visual analog scale.

  • adverse event [ Time Frame: at each visit or contact until 4 weeks after the last dose ]
    Vital signs will be checked at each visit. Laboratory tests will be conducted at baseline and week 8, and at any time if necessary.

Estimated Enrollment: 186
Study Start Date: December 2011
Study Completion Date: June 2013
Primary Completion Date: March 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Fenoverine
Fenoverine 100mg three times a day will be administered for 8 weeks.
Drug: Fenoverine
Fenoverine 100mg three times a day for 8 weeks
Other Name: Fexadin
Active Comparator: Trimebutine
Trimebutine maleate 150mg three times a day will be administered for 8 weeks.
Drug: Timebutine
Timebutine maleate 150mg three times a day for 8 weeks
Other Name: Polybutin

Detailed Description:
For subjects with IBS, Fenoverine and Trimebutine will be administered orally for 8 weeks; Fenoverine 100mg capsule three times a day and Trimebutine 150mg tablet three times a day. Because one is capsule and the other is tablet, double dummy design will be used. Efficacy is evaluated at the end of 8 weeks and safety will be followed for 4 more weeks after the end of the scheduled medication.

Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 18 years of age or older and 60 years of age or younger
  • Diagnosed as irritable bowel syndrome using Rome III Criteria
  • Female subjects of child-bearing potential are confirmed to have a negative urine beta-hCG test within 7 days prior to administration of initial dose of investigational products.
  • Female subjects of child-bearing potential must agree to use contraceptive measures during study period.

Exclusion Criteria:

  • Known allergy or hypersensitivity to investigational products or components of the formulation
  • Past or current diagnosis of chronic liver disease (e.g., liver cirrhosis, acute hepatitis, alcoholic hepatitis, chronic alcohol abuse and HCC)
  • Past or current diagnosis of Myopathy
  • Subject with serious renal disease
  • Known medical condition assessed by investigators as inappropriate for the study
  • Continuous use of NSAIDS, analgesics, steroids, or other immunosuppressants.
  • Continuous use of HMG-CoA reductase inhibitors or fibrates to lower blood lipid level
  • Pregnant, lactating, or planning to be pregnant women
  • Evidence of abuse of drugs or alcohol within 6 months prior to screening
  • Participation in other clinical trials within 3 months prior to enrollment or elapse of less than 5 half lives of previous investigational product after last dose of it.
  • Unable to submit informed consent or comply with the requirements of the study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01507922

Korea, Republic of
Korea University Ansan Hospital
Ansan, Korea, Republic of
Hallym University Sacred Heart Hospital
Anyang, Korea, Republic of
Kangwon National University Hospital
Chuncheon, Korea, Republic of
Gachon University Gil Hospital
Incheon, Korea, Republic of
Inje University Seoul Paik Hospital
Seoul, Korea, Republic of
Korea University Anam Hospital
Seoul, Korea, Republic of
Korea University Guro Hospital
Seoul, Korea, Republic of
Sponsors and Collaborators
Bukwang Pharmaceutical
Principal Investigator: Yoon Tae Jeen, Dr. Korea University Anam Hospital
  More Information

Responsible Party: Bukwang Pharmaceutical Identifier: NCT01507922     History of Changes
Other Study ID Numbers: FEN-401
Study First Received: January 5, 2012
Last Updated: December 17, 2014

Keywords provided by Bukwang Pharmaceutical:
Irritable Bowel Syndrome
Abdominal pain

Additional relevant MeSH terms:
Irritable Bowel Syndrome
Pathologic Processes
Colonic Diseases, Functional
Colonic Diseases
Intestinal Diseases
Gastrointestinal Diseases
Digestive System Diseases
Maleic acid
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents processed this record on April 28, 2017